Introduction
Biliary tract cancers (BTCs) are rare but fatal. In the USA in 2017, the estimated number of new cancer cases from gallbladder and other biliary tissue was 11,740 (5,320 in males; 6,420 in females) and the estimated number of deaths was 3,830 (1,630 in males; 2,200 in females). 1 In People's Republic of China in 2015, estimates of gallbladder cancer incidence and mortality were 52,800 (24, 
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Ma et al 28,300 in females) and 40,700 (18,800 in males; 21,800 in females), respectively. 2 Tumors of the biliary tract typically have a poor prognosis, with 5-year survival rates in the range of 5%-15%. 3, 4 According to the primary site, BTCs encompass gallbladder carcinoma (GBC), distal bile duct (DBD) carcinoma, intrahepatic cholangiocarcinoma (IHC), and hilar cholangiocarcinoma.
Surgical resection is reported to be the only potential method for curative treatment of BTC. 5, 6 Data supporting an adjuvant approach are sparse. The Phase III UK Advanced Biliary Cancer-02 (ABC-02) study confirmed the combination of cisplatin with gemcitabine as the standard treatment for advanced BTC. 7 Targeting angiogenesis and HER2/ neu blockade have been shown to be promising treatment strategies for BTC patients. 8, 9 However, prognostic factors among BTC patients remain scarce. R0 resection and adjuvant chemotherapy may be prognosticators of long-term survival for patients with cholangiocarcinoma. [10] [11] [12] Despite surgical resection, recent reports concerning postoperative prognosis are unsatisfactory, with a 5-year survival rate of 27%-37% for DBD carcinoma, 22%-44% for IHC, and 11%-41% for hilar cholangiocarcinoma. [13] [14] [15] [16] [17] Therefore, the prognostic factors that predict long-term survival of BTC patients undergoing radical surgery are essential.
Serum tumor markers, including carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA), have been used as a complementary approach for the diagnosis of BTC in conjunction with radiology and histology/ cytology. [18] [19] [20] Likewise, lactic dehydrogenase (LDH) is a glycolytic enzyme that is essential for tumor maintenance and can be used as an attractive antitumor strategy by inhibiting glucose metabolism. 21 LDH is reported to be associated with the hypoxia-inducible factor (HIF) pathway, hypoxia, acidity, and neoangiogenesis. 22 Serum LDH levels can provide prognostic information on overall survival (OS) in patients with advanced pancreatic cancer, colorectal cancer, and melanoma. [23] [24] [25] [26] However, the prognostic roles of tumor markers including CEA, CA19-9, and LDH have not yet been clearly elucidated in operable BTC.
The aim of this study was to investigate the role of tumor markers in predicting clinical outcome for BTC patients who have undergone radical surgery. It was hypothesized that elevated baseline serum LDH is prognostic of diminished OS in operable BTC, especially in operable DBD carcinoma.
Methods

study population and data collection
Patients who were diagnosed with BTC at The First Affiliated Hospital of Nanjing Medical University from January 2011 to December 2015 were enrolled in this study. All patients were histologically confirmed with BTC. Due to a potentially different biology, 27 ampullary tumors were not included in this study. Exclusion criteria were as follows: 1) BTC patients with concurrent primary tumors of other types, 2) patients with missing or incomplete interest data, 3) patients with advanced BTC, and 4) patients who expired within the first month after surgery due to postoperative complications. In total, 341 patients were eligible for the analysis and were followed until December 2016 (Figure 1) .
The baseline demographics that were evaluated in this study included age, sex, site of primary tumor (DBD, GBC, IHC, or hilar), depth of tumor invasion, lymph node status, metastasis, stage, histologic differentiation, lymphovascular invasion, perineural invasion, surgical margin status, hemoglobin, CEA, CA19-9, and LDH at diagnosis (prior to surgery). A CEA level of 4.7 ng/mL, CA 19-9 level of 
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Prognostic factors for operable biliary tract cancer 39 U/mL, and LDH level of 271 U/L were defined as cutoff values for normal levels according to the historical data and manufacturer's recommendations. 28, 29 Stage classification was based on pathological findings and documented according to the seventh edition of the Union for International Cancer Control tumor-node-metastasis staging system. 30 The protocol was approved by the Ethics Committee of The First Affiliated Hospital of Nanjing Medical University prior to study initiation and conformed to the provisions of the Declaration of Helsinki (as revised in Fortaleza, Brazil, October 2013). Written informed consent was obtained from all patients. statistics Continuous variables were described as median (interquartile range [IQR] ). OS was defined as the period from the day of operation to death or the last follow-up (December 2016). The OS of all patients in this study was analyzed and recorded. Survival distribution was estimated by the Kaplan-Meier method. The log-rank test was used to evaluate the equality of survivor functions across groups. The Cox proportional hazards model was used with a 95% CI for the univariate and multivariate analyses. The chi-square test was used to compare baseline characteristics of patients between the LDH groups. All statistical tests were two-sided. Statistical significance was defined as P , 0.05. All analyses were performed using SPSS software for Windows (version 19; IBM SPSS, Somers, NY, USA). 
Results
Patients
Outcomes in the entire cohort
To investigate whether the patient baseline characteristics and laboratory factors were associated with survival of 
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Prognostic factors for operable biliary tract cancer (Table 3 and Figure 2 ). However, using univariate analysis, sex, metastasis, CEA, and CA19-9 were not statistically significant in OS in patients with radical surgery of BTC. Compared to LDH ,271 U/L, LDH $271 U/L was associated with a worse OS using univariate analysis (HR-1.435, 95% CI; 1.038-1.982, P = 0.029). Moreover, LDH retained its significance as a prognostic marker in multivariate analysis (HR-1.505, 95% CI; 1.009-2.245, P = 0.045) in the entire cohort along with age, depth of tumor invasion, resection margin, and hemoglobin (Table 3) .
comparison between high and low lDh groups Figure 2E ).
Patients showing a pretreatment serum LDH ,271 U/L were classified as LDH-low patients (251 patients, 73.6%, group A), whereas patients with pretreatment serum LDH level $271 U/L were classified as LDH-high patients (90 patients, 26.4%, group B). The patients with positive lymphovascular invasion and positive perineural invasion were more frequently found in the high LDH group (P = 0.010, P = 0.031, respectively) ( Table 4) .
Outcomes by BTc site
Considering the tumor primary site, it was further determined whether serum LDH retained its significance as a prognostic marker in BTC subgroups separately. The results showed that LDH was prognostic in multivariate analysis for the DBD subgroup (HR-2.452, 95% CI; 1.167-5.152, P = 0.018) ( Table 5 ). The data showed a nonsignificant improvement in survival with LDH ,271 U/L compared with LDH $271 U/L in multivariate model in individual subgroups: GBC (Table S1 ) or hilar cancer (Table S2) . Moreover, in multivariate analysis, age (P = 0.003) and depth of tumor invasion (P = 0.020) showed a significant association with OS in GBC (Table S1 ). Since there was a limited number of patients in the IHC subgroup, the corresponding multivariate analysis was not available. Details of multivariate analysis outcomes for OS by BTC site are provided in Tables 5, S1 , and S2. 
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Ma et al Figure 2 Kaplan-Meier analysis of overall survival. Notes: Unadjusted overall survival curves for independent factors by univariate analyses: depth of tumor invasion (A), age (B), resection margin (C), pre-hb (D), and pre-lDh (E). Abbreviations: pre-, preoperative; hb, hemoglobin; lDh, lactic dehydrogenase; T, depth of tumor invasion; r0, positive resection margin; r1, negative resection margin.
Discussion
Surgical resection offers the only potentially curative option for BTC, 5 while postoperative prognosis is unsatisfactory after extensive surgical resection. [13] [14] [15] [16] Moreover, the prognostic role of tumor markers has not yet been clearly elucidated in BTC patients undergoing radical surgery. Therefore, it is significant to identify prognostic factors that predict long-term survival of BTC patients who have undergone radical surgery. LDH has been reported to be a prognosticator in various types of tumors. 22, 24, 26 Some studies suggest a prognostic role of LDH in patients with advanced BTC receiving certain chemotherapy. 31, 32 However, the prognosis of LDH in BTC patients undergoing radical surgery and in different tumor primary sites remains unclear. The present study revealed that high serum LDH level is significantly associated with worse survival in patients with operable BTC.
In our study, we discovered the prognostic roles of age, depth of tumor invasion, surgical margin status, hemoglobin, and serum LDH level for OS in multivariate analysis in the entire cohort of 341 patients surgically treated for BTC. Pradeep et al 33 found that age was a significant predictor of survival by multivariate analysis in analyzing prognostic factors in 87 patients with GBC. Cubertafond et al 34 reported in a survey of 724 patients surgically treated submit your manuscript | www.dovepress.com
Dovepress
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Ma et al for GBC that the long-term survival correlated with cancer stage: .60 months, .22 months, and 8 months for Tis, T1 to T2, and T3 to T4, respectively. R0 resection is reported to be prognosticator of long-term survival for patients with cholangiocarcinoma. 10 These studies were consistent with our findings. CA19-9 and CEA have been used as a complementary approach for the diagnosis of BTC in conjunction with radiology and histology/cytology, [18] [19] [20] while the prognostic roles for better survival remain controversial. Lee et al 35 suggested that CA19-9 but not CEA served as a predictor of better survival in patients with advanced cholangiocarcinoma on gemcitabine-based chemotherapy. Peixoto et al 36 reported that CA19-9 and CEA were not significantly associated with OS in 106 patients with advanced BTC using univariate analysis. Our study showed a nonsignificant trend for better survival of patients with a low level of CA19-9 or CEA. The prognostic roles of CA19-9 and CEA for survival in BTC patients have to be further validated with a larger number of patients and prospective studies.
Moreover, we found that LDH is predictive of poor prognosis and clinical outcome in BTC patients undergoing radical surgery. In addition, Faloppi et al 37 showed a possible prognostic role of pretreatment serum LDH levels in advanced BTC patients treated with first-line chemotherapy, confirming our hypothesis. In a Phase II study, Furuse et al 31 revealed that elevated serum LDH level was associated with a significantly shorter survival in 85 patients with unresectable BTC receiving combination chemotherapy of uracil-tegafur and doxorubicin (P = 0.043). Moreover, these findings are in accordance with previously published analyses suggesting a relationship between LDH levels and a worse outcome in other tumor types. 22, 23, 38 Furthermore, our study revealed that serum LDH can be a prognostic marker for DBD carcinoma. However, in terms of other primary tumors originating from the biliary tract, there were no statistically significant differences between LDH and OS in multivariate analysis in individual subgroups. The results indicated the possibility of different origins and biological behavior among these primary sites. Alternatively, this may be due to the limited number of patients in this study. Future studies may require greater numbers of patients to be considered statistically significant. The ABC-02 trial demonstrated that the site of the primary tumor within the biliary tract did not affect survival. Hypoxia-induced angiogenesis is probably the mechanism involved in high serum LDH levels and poor prognosis. 22 Published studies demonstrated the association between LDH5 up-regulation and HIF (HIF1α/HIF2α) accumulation, which is linked with activating transcription of multiple genes including those encoding glycolytic enzymes and vascular endothelial growth factor. 21, 39 In addition, activated HIF pathway and angiogenic factor production are correlated with enhanced tumor aggressiveness.
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Conclusion
These data shed light on older age, depth of tumor invasion, positive surgical margin status, lower hemoglobin, and elevated serum LDH level as prognostic factors for poor survival in operable BTC patients. Moreover, serum LDH could be used as a cost-effective prognostic biomarker for DBD cancer. A limitation of this study is its retrospective nature, which means it lacks availability of some data, but it is reflective of the clinical spectrum of Chinese patients and is a relatively large study on this rare tumor type. In addition, this analysis is a single institutional series. These findings might provide new opportunities for prospective multi-institutional trials toward clinical applications of serum LDH in BTC patients undergoing radical surgery.
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